SCHEMBL4389544

SCHEMBL4389544

COCC1C(=O)N(Cc2ccc3c(N)ncnc3c2)C(C)CN1C(=O)COc1csc(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
F10 P00742 12/20 0.39
CCR1 P32246 6/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1651529 1.00 F10 (0.39) F10CCR1
SCHEMBL1386985 0.91 F10 (0.39) F10CCR1
SCHEMBL1386572 0.91 F10 (0.39) F10CCR1
SCHEMBL1386982 0.91 F10 (0.39) F10CCR1
SCHEMBL1386574 0.91 F10 (0.39) F10CCR1
SCHEMBL1651474 0.90 F10 (0.41) F10CCR1
SCHEMBL4386998 0.90 F10 (0.41) F10CCR1
SCHEMBL1652552 0.89 F10 (0.40) F10CCR1
SCHEMBL4391704 0.89 F10 (0.40) F10CCR1
SCHEMBL1651577 0.88 F10 (0.41) F10CCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US claimed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102450-A1 Substituted oxoazaheterocyclyl compounds F13B, F9, F11 F10 12/4885CCR1 2932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.